Interaction Checker

Temsirolimus interactions

Temsirolimus (Torisel) has 215 documented interactions across the FDA labels and fact sheets we index: 2 major, 212 moderate, 1 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (2)

  • CarbamazepineanticonvulsantMajor

    Temsirolimus The use of concomitant strong CYP3A4 inducers such as carbamazepine should be avoided with temsirolimus. (Carbamazepine label, Drug interactions)

  • Itraconazoleazole antifungalMajor

    Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment. (Itraconazole label, Drug interactions)

Moderate interactions (212)

  • AbataceptimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • AbrocitinibJAK inhibitorModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • AcarboseantidiabeticModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • AdalimumabimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • AlemtuzumabimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • AlogliptinDPP-4 inhibitorModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • Alogliptin and metforminDPP-4 inhibitorModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • AmiodaroneantiarrhythmicModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • Amlodipinedihydropyridine calcium channel blockerModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • Amlodipine and atorvastatindihydropyridine calcium channel blockerModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • Amlodipine and benazeprildihydropyridine calcium channel blockerModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • Amlodipine and olmesartandihydropyridine calcium channel blockerModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • Amlodipine and valsartandihydropyridine calcium channel blockerModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • AprepitantCYP3A4 inhibitorModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • ArmodafinilCNS stimulantModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • AtazanavirantiretroviralModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • AzathioprineimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • AzelastineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • Azelastine and fluticasoneantihistamineModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • BaricitinibJAK inhibitorModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • BeclomethasonecorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • BenazeprilACE inhibitorModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • Benazepril and hydrochlorothiazideACE inhibitorModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • BetamethasonecorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • BexagliflozinSGLT2 inhibitorModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • BosentanCYP3A4 inducerModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • Brompheniramine, pseudoephedrine, and dextromethorphanantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • BudesonidecorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • Budesonide and formoterolcorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • CanagliflozinSGLT2 inhibitorModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • CaptoprilACE inhibitorModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • CarbinoxamineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • CenobamateanticonvulsantModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • CetirizineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • ChlorpheniramineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • CiclesonidecorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • CimetidineH2 blockerModerate

    …physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (Temsirolimus label, Warnings and precautions)

  • CladribineantimetaboliteModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • Clarithromycinmacrolide antibioticModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • ClemastineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • ClobazambenzodiazepineModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • ClobetasolcorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • CyclophosphamideimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • CyclosporineimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • CyproheptadineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • DapagliflozinSGLT2 inhibitorModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • Dapagliflozin and metforminSGLT2 inhibitorModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • DarunavirantiretroviralModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • Darunavir and cobicistatantiretroviralModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • Deferasiroxiron supplementModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • DeflazacortcorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • DesloratadineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • DesonidecorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • DexamethasonecorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • DexchlorpheniramineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • Diltiazemcalcium channel blockerModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • DimenhydrinateantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • Dimethyl fumarateimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • DiphenhydramineantihistamineModerate

    At the discretion of the physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting… (Temsirolimus label, Warnings and precautions)

  • DoxylamineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • Doxylamine and pyridoxineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • DronedaroneantiarrhythmicModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • DulaglutideGLP-1 receptor agonistModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • EfavirenzantiretroviralModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • Efavirenz, lamivudine, and tenofovirantiretroviralModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • Elvitegravir, cobicistat, emtricitabine, and tenofovirantiretroviralModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • EmpagliflozinSGLT2 inhibitorModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • Empagliflozin and metforminSGLT2 inhibitorModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • EnalaprilACE inhibitorModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • Enalapril and hydrochlorothiazideACE inhibitorModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • EnalaprilatACE inhibitorModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • Erythromycinmacrolide antibioticModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • EslicarbazepineanticonvulsantModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • EtanerceptimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • EtravirineantiretroviralModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • EverolimusimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • ExenatideGLP-1 receptor agonistModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • FamotidineH2 blockerModerate

    …physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (Temsirolimus label, Warnings and precautions)

  • Felodipinedihydropyridine calcium channel blockerModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • FexofenadineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • FingolimodimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • Fluconazoleazole antifungalModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • FludrocortisonecorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • FlunisolidecorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • FluocinonidecorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • FluticasonecorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • Fluticasone and salmeterolcorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • FosamprenavirantiretroviralModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • FosaprepitantCYP3A4 inhibitorModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • FosinoprilACE inhibitorModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • Fosinopril and hydrochlorothiazideACE inhibitorModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • FosphenytoinanticonvulsantModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • GlimepiridesulfonylureaModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • GlipizidesulfonylureaModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • Glipizide and metforminsulfonylureaModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • GlyburidesulfonylureaModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • Glyburide and metforminsulfonylureaModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • GriseofulvinantifungalModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • GuselkumabimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • HalobetasolcorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • Hydrocodone and chlorpheniramineopioidModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • HydrocortisonecorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • HydroxyzineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • Ibuprofen and famotidineNSAIDModerate

    …physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (Temsirolimus label, Warnings and precautions)

  • ImatinibCYP3A4 inhibitorModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • InfliximabimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • Insulin aspartinsulinModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • Insulin degludecinsulinModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • Insulin detemirinsulinModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • Insulin glargineinsulinModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • Insulin lisproinsulinModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • Insulin regular (human)insulinModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • IsoniazidantibioticModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • Isradipinedihydropyridine calcium channel blockerModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • IvacaftorCYP3A4 inhibitorModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • Ketoconazoleazole antifungalModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • LeflunomideimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • LenacapavirantiretroviralModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • LevocetirizineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • LinagliptinDPP-4 inhibitorModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • Linagliptin and metforminDPP-4 inhibitorModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • LiraglutideGLP-1 receptor agonistModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • LisinoprilACE inhibitorModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • Lisinopril and hydrochlorothiazideACE inhibitorModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • Lopinavir and ritonavirantiretroviralModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • LoratadineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • LorlatinibCYP3A4 inducerModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • MeclizineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • MercaptopurineantimetaboliteModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • MetforminbiguanideModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • MethotrexateimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • MethylprednisolonecorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • MifepristoneCYP3A4 inhibitorModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • MiglitolantidiabeticModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • Mirabegronbeta-adrenergic agonistModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • MitapivatCYP3A4 inducerModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • MitotaneCYP3A4 inducerModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • ModafinilCNS stimulantModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • MoexiprilACE inhibitorModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • MometasonecorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • MycophenolateimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • Nafcillinpenicillin antibioticModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • NatalizumabimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • NateglinidemeglitinideModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • NefazodoneantidepressantModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • NevirapineantiretroviralModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • Nicardipinedihydropyridine calcium channel blockerModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • Nifedipinedihydropyridine calcium channel blockerModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • Nimodipinedihydropyridine calcium channel blockerModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • Nirmatrelvir and ritonavirantiviralModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • Nisoldipinedihydropyridine calcium channel blockerModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • NizatidineH2 blockerModerate

    …physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (Temsirolimus label, Warnings and precautions)

  • OcrelizumabimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • Olmesartan, amlodipine, and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • OlopatadineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • Olopatadine and mometasoneantihistamineModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • OxcarbazepineanticonvulsantModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • PalbociclibCYP3A4 inhibitorModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • PerampanelanticonvulsantModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • PerindoprilACE inhibitorModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • PhenobarbitalbarbiturateModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • Phenobarbital, hyoscyamine, atropine, and scopolaminebarbiturateModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • Phentermine and topiramateCNS stimulantModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • PhenytoinanticonvulsantModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • Pimecrolimuscalcineurin inhibitorModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • PioglitazonethiazolidinedioneModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • Pioglitazone and glimepiridethiazolidinedioneModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • Pioglitazone and metforminthiazolidinedioneModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • PonesimodimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • Posaconazoleazole antifungalModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • PrednisolonecorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • PrednisonecorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • PrimidoneanticonvulsantModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • PromethazineantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • Promethazine and codeineopioidModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • Promethazine and dextromethorphanantihistamineModerate

    TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (Temsirolimus label, Warnings and precautions)

  • QuinaprilACE inhibitorModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • Quinapril and hydrochlorothiazideACE inhibitorModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • RamiprilACE inhibitorModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • RanitidineH2 blockerModerate

    …physician, treatment may be resumed with the administration of an H 1 -receptor antagonist (such as diphenhydramine), if not previously administered [see Dosage and Administration (2.2) ] , and/or an H 2 -receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. (Temsirolimus label, Warnings and precautions)

  • RanolazineQT-prolonging drugModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • RepaglinidemeglitinideModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • RifabutinantibioticModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • RifampinantibioticModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • RifapentineantibioticModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • RitlecitinibJAK inhibitorModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • RitonavirantiretroviralModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • RituximabimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • SaxagliptinDPP-4 inhibitorModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • Saxagliptin and metforminDPP-4 inhibitorModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • SecukinumabimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • SemaglutideGLP-1 receptor agonistModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • SirolimusimmunosuppressantModerate

    TORISEL should be used with caution in persons with known hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any other component (including the excipients) of TORISEL. (Temsirolimus label, Warnings and precautions)

  • SitagliptinDPP-4 inhibitorModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • Sitagliptin and metforminDPP-4 inhibitorModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • SunitinibModerate

    Concomitant use of TORISEL with sunitinib The combination of TORISEL and sunitinib resulted in dose-limiting toxicity. (Temsirolimus label, Warnings and precautions)

  • Suvorexantsedative-hypnoticModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • SuzetrigineCYP3A4 inducerModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • TacrolimusimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • Telmisartan and amlodipineangiotensin II receptor blocker (ARB)Moderate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • TeriflunomideimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • Ticagrelorantiplatelet agentModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • TirzepatideGLP-1 receptor agonistModerate

    This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (Temsirolimus label, Warnings and precautions)

  • TocilizumabimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • TofacitinibimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • TopiramateanticonvulsantModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • TrandolaprilACE inhibitorModerate

    Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus label, Drug interactions)

  • TriamcinolonecorticosteroidModerate

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (Temsirolimus label, Warnings and precautions)

  • UpadacitinibimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • UstekinumabimmunosuppressantModerate

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus label, Warnings and precautions)

  • Verapamilcalcium channel blockerModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

  • Voriconazoleazole antifungalModerate

    Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (Temsirolimus label, Warnings and precautions)

Minor mentions (1)

  • Desipraminetricyclic antidepressantMinor

    Drug Interactions Effect of Temsirolimus on CYP2D6 or CYP3A The concentration of desipramine, a CYP2D6 substrate, was unaffected when 25 mg of temsirolimus was co-administered. (Temsirolimus label, Drug interactions)

Check Temsirolimus against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.